Logo - springer
Slogan - springer

Statistics - Life Sciences, Medicine & Health | The Evaluation of Surrogate Endpoints

The Evaluation of Surrogate Endpoints

Burzykowski, Tomasz, Molenberghs, Geert, Buyse, Marc (Eds.)

2005, XXIV, 410 p.

Available Formats:
eBook
Information

Springer eBooks may be purchased by end-customers only and are sold without copy protection (DRM free). Instead, all eBooks include personalized watermarks. This means you can read the Springer eBooks across numerous devices such as Laptops, eReaders, and tablets.

You can pay for Springer eBooks with Visa, Mastercard, American Express or Paypal.

After the purchase you can directly download the eBook file or read it online in our Springer eBook Reader. Furthermore your eBook will be stored in your MySpringer account. So you can always re-download your eBooks.

 
$139.00

(net) price for USA

ISBN 978-0-387-27080-7

digitally watermarked, no DRM

Included Format: PDF

download immediately after purchase


learn more about Springer eBooks

add to marked items

Hardcover
Information

Hardcover version

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$179.00

(net) price for USA

ISBN 978-0-387-20277-8

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Softcover
Information

Softcover (also known as softback) version.

You can pay for Springer Books with Visa, Mastercard, American Express or Paypal.

Standard shipping is free of charge for individual customers.

 
$179.00

(net) price for USA

ISBN 978-1-4419-1906-9

free shipping for individuals worldwide

usually dispatched within 3 to 5 business days


add to marked items

Both humanitarian and commercial considerations have spurred intensive search for methods to reduce the time and cost required to develop new therapies. The identification and use of surrogate endpoints, i.e., measures that can replace or supplement other endpoints in evaluations of experimental treatments or other interventions, is a general strategy that has stimulated both enthusiasm and skepticism. Surrogate endpoints are useful when they can be measured earlier, more conveniently, or more frequently than the "true" endpoints of primary interest. Regulatory agencies around the globe, particularly in the United States, Europe, and Japan, are introducing provisions and policies relating to the use of surrogate endpoints in registration studies. But how can one establish the adequacy of a surrogate? What kind of evidence is needed, and what statistical methods portray that evidence most appropriately?

This book offers a balanced account on this controversial topic. The text presents major developments of the last couple of decades, together with a unified, meta-analytic framework within which surrogates can be evaluated from several angles. Methodological development is coupled with perspectives on various therapeutic areas. Academic views are juxtaposed with standpoints of scientists working in the biopharmaceutical industry as well as of colleagues from the regulatory authorities.

Tomasz Burzykowski is Assistant Professor of Biostatistics at the Limburgs Universitair Centrum in Belgium. Dr. Burzykowski has published methodological work on the analysis of survey data, meta-analyses of clinical trials, and validation of surrogate endpoints. He is a co-author of numerous papers applying statistical methods to clinical data in different disease areas (cancer, cardiovascular diseases, dermatology, orthodontics).

Geert Molenberghs is Professor of Biostatistics at the Limburgs Universitair Centrum in Belgium. Dr. Molenberghs published methodological work on surrogate markers in clinical trials, categorical data, longitudinal data analysis, and on the analysis of non-response in clinical and epidemiological studies. He serves as Joint Editor for Applied Statistics (2001-2004) and is President of the International Biometric Society (2004-2005). He was elected Fellow of the American Statistical Association and received the Guy Medal in Bronze from the Royal Statistical Society.

Marc Buyse founded the International Drug Development Institute in 1991. He is Past President of the International Society for Clinical Biostatistics, Past President of the Quetelet Society, and Past Board Member of the Society for Clinical Trials. He is currently the Executive Director of IDDI (International Drug Development Institute) and Associate Professor of biostatistics at the Limburgs Universitair Centrum, Center for Statistics, Diepenbeek, Belgium. He has published extensively in the fields of biostatistics and oncology. His research interests include meta-analysis, surrogate endpoints, statistical detection of fraud, and the design and statistical analysis of clinical trials.

Content Level » Professional/practitioner

Keywords » cancer - data analysis - dermatology - diseases - oncology - statistics - therapy

Related subjects » Life Sciences, Medicine & Health

Table of contents 

Introduction * Setting the Scene * Regulatory Aspects in Using Surrogate Markers in Clinical Trials * Notation and Motivating Studies * The History of Surrogate Marker Validation * Validation Using Single-Trial Data: Mixed Binary and Continuous Outcomes * A Meta-Analytic Validation Framework for Contiuous Outcomes * The Choice of Units * Extensions of the Meta-Analytic Approach to Surrogate Endpoints * Meta-Analytic Validation with Binary Outcomes * Validation in the Case of Two Failure-Time Endpoints * An Ordinal Surrogate for a Survival True Endpoint * A Combination of Longitudinal and Survival Endpoints * Repeated Measures and Surrogate Marker Validation * Bayesian Evaluation of Surrogate Endpoints * Surrogate Marker Validation in Mental Health * The Evaluation of Surrogate Endpoints in Practice: Experience in HIV * An Alternative Measure for Meta-Analytic Surrogate Marker Validation * Discussion: Surrogate Endpoint Definition and Evaluation *The Promise and Peril of Surrogate End Points in Cancer Research

Popular Content within this publication 

 

Articles

Read this Book on Springerlink

Services for this book

New Book Alert

Get alerted on new Springer publications in the subject area of Statistics for Life Sciences, Medicine, Health Sciences.